Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 153 participants.
Also called NCT04595370
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 153 participants
- Sponsor
- Registry
-
NCT04595370 -
2020-003126-23
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Belgium, Bulgaria, Canada, Czechia, Denmark, Germany, Hungary, India, Italy, Japan, Lithuania, Poland, Russia, Slovakia, South Korea, Spain, Sweden, Taiwan, Thailand, Türkiye, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT04595370. Randomized; quadruple masking; primary purpose treatment. Start 2021-01-26 (actual); primary completion 2023-09-22 (actual). Results posted on 2024-11-19.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease
- Acronym
- MIRACLE
- Condition
- Heart Failure
- Condition
- Chronic Kidney Disease
- Intervention (Drug)
- AZD9977
- Intervention (Drug)
- Dapagliflozin
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct04595370- Content hash
78899c04591de25f1b3624cbf62b5ab87526ed54f23ad3c9f1eb918646093c8a